KyoungSoo Lim
Research Subjects
KyoungSoo Lim has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Diansong Zhou
AstraZeneca Waltham Massachusetts USA
16 shared publications - Alejandra Negro
Oncology R&D, AstraZeneca, Gaithersburg, Maryland
15 shared publications - Anis A. Khan
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca Gaithersburg Maryland USA
15 shared publications - Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center, New York, New York, USA
15 shared publications - John F. Kurland
Oncology R&D, AstraZeneca, Gaithersburg, Maryland
15 shared publications - Kun Wang
Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China
15 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Geometric mean serum concentration-time profiles of rilvegostomig by dose (PK analysis set).
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Geometric mean serum concentration-time profiles of rilvegostomig by dose (PK analysis set).
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Patient disposition in Part A and Part B of ARTEMIDE-01.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Patient disposition in Part A and Part B of ARTEMIDE-01.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Kaplan-Meier plot of PFS with rilvegostomig.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Kaplan-Meier plot of PFS with rilvegostomig.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Inclusion and exclusion criteria for Parts A and B of ARTEMIDE-01 study.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Inclusion and exclusion criteria for Parts A and B of ARTEMIDE-01 study.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Supplementary Methods and Materials.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods1 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Supplementary Methods and Materials.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Patient demographics and baseline disease characteristics in Part A by dose level.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Patient demographics and baseline disease characteristics in Part A by dose level.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Representativeness of study participants.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Representativeness of study participants.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Summary of rilvegostomig safety profile in Part A by dose level.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Summary of rilvegostomig safety profile in Part A by dose level.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Anti-drug antibody responses (immunogenicity analysis set).
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Anti-drug antibody responses (immunogenicity analysis set).
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Summary of antitumor activity and PFS in Part A by dose level.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Rilvegostomig for Metastatic Non–Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study
Summary of antitumor activity and PFS in Part A by dose level.